New MRI methods to measure metabolism and predict outcomes in metabolic-associated fatty liver disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study that collects clinical, imaging, laboratory, and pathological data from people with metabolism-related fatty liver disease. Participants undergo MR imaging and the resulting scans are processed with advanced image-analysis software to extract quantitative imaging parameters and body-composition metrics. Investigators will look for links between those imaging measures, metabolic disorders, and disease severity to support non-invasive diagnosis, treatment monitoring, and prognosis prediction. The goal is to generate imaging biomarkers that can help guide clinical care and improve patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with MR examination are clinically suspected or diagnosed with metabolism-related fatty liver disease;
2. Age/gender: unlimited;
3. Patients who voluntarily participate in clinical trials and sign written subject informed consent

Exclusion Criteria:

1. Clinical suspicion or diagnosis of metabolism-related fatty liver disease and having been prescribed an MR examination;
2. Voluntarily participation in the study and provision of written informed consent.

Where it's running

• Tongji hospital
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Zhen Li
• Email: zhenli@hust.edu.cn
• Phone: 02783663543

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining genetics, blood, urine, and stool data to predict complications of metabolic syndrome

  The team will try combining genetic, blood, urine, and stool data to see if patterns predict complications in adults with or without metabolic syndrome.

  Recruiting Chang Gung Memorial Hospital · Taoyuan · NCT07248371

• Glucagon resistance in MASLD and type 2 diabetes

  This will see if people with type 2 diabetes, with or without MASLD, respond differently to glucagon in liver fat oxidation and VLDL-triglyceride secretion.

  Recruiting University of Aarhus · Aarhus · NCT07246421

• ERCG (clip-and-loop endoscopic gastric reduction) versus optimized lifestyle for weight loss

  This trial will test whether ERCG, a sutureless endoscopic clip-and-loop procedure that reduces stomach volume, helps Chinese adults with BMI 24.0–37.4 kg/m² lose more weight than an optimized lifestyle program.

  Recruiting Beijing 302 Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07237750

• Rifaximin treatment for metabolic-associated fatty liver disease

  This trial tests whether taking oral rifaximin for 24 weeks helps adults with metabolic-associated fatty liver disease (MAFLD) and is safe.

  Recruiting Early Phase 1 Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT07185932

• Non-invasive blood and imaging tests for metabolic liver disease

  This project tests whether blood tests and imaging scans can diagnose and stage metabolic-associated steatohepatitis (MASH) and liver fibrosis in adults with metabolic risk factors.

  Recruiting at 4 sites Foundation for the National Institutes of Health · Miami, Florida and 3 other locations · NCT07122700

• Low‑methoxy pectin for inflammation, gut microbiome, and metabolic health in MASLD

  This tests whether taking daily low‑methoxy pectin for six weeks can reduce inflammation and improve gut bacteria and metabolic markers in adults with MASLD.

  Recruiting at 3 sites University of Nottingham · Nottingham, United Kingdom and 2 other locations · NCT07093346

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.